Premium
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE‐2 and AMAGINE‐3
Author(s) -
Reich K.,
Hansen J.B.,
Puig L.,
Konstantinou M.P.,
Warren R.B.
Publication year - 2021
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.17433
Subject(s) - medicine , ustekinumab , psoriasis area and severity index , psoriasis , cumulative incidence , population , disease , dermatology , adalimumab , cohort , environmental health
Background The pathway for treatment of psoriasis is partly dependent upon disease severity, and patients may experience inadequate response at any point along the treatment pathway. Patients who repeatedly fail therapy represent a population in whom effective and well‐tolerated treatment options are limited. Objectives To investigate and describe patients achieving Psoriasis Area and Severity Index (PASI) 100 and cumulative treatment benefit over time in patients with moderate‐to‐severe psoriasis receiving brodalumab or ustekinumab by prior treatment. Methods We conducted a post hoc analysis of data from two phase 3, randomized, controlled, 52‐week AMAGINE trials of brodalumab to describe patients who achieved complete clearance as measured by PASI 100 by prior treatment subgroup (naïve to systemic and biologic treatment, systemic‐treated but biologic‐naïve, biologic‐treated without failure, and biologic‐treated with failure). A competing risk model was used to assess cumulative incidence over a 52‐week period with outcomes of PASI 100 or inadequate response. Cumulative clinical benefit of treatment was determined with an area under the curve analysis. Results The 52‐week cumulative incidence of patients achieving PASI 100 was consistently higher for brodalumab vs. ustekinumab across treatment pathway subgroups (76% vs. 58% in systemic/biologic‐naïve patients, 78% vs. 55% in systemic‐treated/biologic‐naïve patients, 75% vs. 41% in biologic‐treated patients without failure, and 70% vs. 30% in biologic‐treated patients with failure). Rates of inadequate response were lower with brodalumab compared with ustekinumab across all subgroups. Cumulative treatment benefit was also higher for all subgroups treated with brodalumab compared with those treated with ustekinumab. Conclusion Treatment with brodalumab was associated with higher levels of complete clearance and greater cumulative benefit over time compared with ustekinumab, in patients with moderate‐to‐severe psoriasis, regardless of prior treatment experience.